Microvascular Dysfunction Is Associated With Worse Cognitive Performance The Maastricht Study by Rensma, Sytze P. et al.
 
 
 
Microvascular Dysfunction Is Associated With Worse
Cognitive Performance The Maastricht Study
Citation for published version (APA):
Rensma, S. P., van Sloten, T. T., Houben, A. J. H. M., Koehler, S., van Boxtel, M. P. J., Berendschot, T.
T. J. M., Jansen, J. F. A., Verhey, F. R. J., Kroon, A. A., Koster, A., Backes, W. H., Schaper, N., Dinant,
G-J., Schalkwijk, C. G., Henry, R. M. A., Wolfs, E. M. L., van Heumen, M. J. A., Schram, M. T., &
Stehouwer, C. D. A. (2020). Microvascular Dysfunction Is Associated With Worse Cognitive Performance
The Maastricht Study. Hypertension, 75(1), 237-245.
https://doi.org/10.1161/HYPERTENSIONAHA.119.13023
Document status and date:
Published: 01/01/2020
DOI:
10.1161/HYPERTENSIONAHA.119.13023
Document Version:
Publisher's PDF, also known as Version of record
Document license:
Taverne
Please check the document version of this publication:
• A submitted manuscript is the version of the article upon submission and before peer-review. There can
be important differences between the submitted version and the official published version of record.
People interested in the research are advised to contact the author for the final version of the publication,
or visit the DOI to the publisher's website.
• The final author version and the galley proof are versions of the publication after peer review.
• The final published version features the final layout of the paper including the volume, issue and page
numbers.
Link to publication
General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright
owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these
rights.
• Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
• You may not further distribute the material or use it for any profit-making activity or commercial gain
• You may freely distribute the URL identifying the publication in the public portal.
If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the “Taverne” license above,
please follow below link for the End User Agreement:
www.umlib.nl/taverne-license
Take down policy
If you believe that this document breaches copyright please contact us at:
repository@maastrichtuniversity.nl
providing details and we will investigate your claim.
Download date: 07 Jan. 2021
237
Cognitive impairment and dementia are major health prob-lems, and their prevalence rises with the aging of the pop-
ulation.1 The mechanisms underlying cognitive impairment 
remain, however, incompletely understood, and may include 
microvascular dysfunction and damage (MVD).2
The microvasculature is involved in the regulation of many 
cerebral processes, notably neurovascular coupling, cerebral 
autoregulation, blood-brain barrier permeability, and neuro-
genesis.2 Impairment of these processes may lead to neuronal 
dysfunction, ischemia and cell death, which may contribute to 
cognitive impairment.2
Microvascular function can be measured noninvasively in 
various organs. Indirect measures include magnetic resonance 
imaging (MRI) features of cerebral small vessel disease (CSVD, 
eg, total brain parenchyma volume, white matter hyperintensity 
volume, and presence of lacunar infarcts and cerebral micro-
bleeds)3; plasma biomarkers of MVD (eg, sICAM-1 [soluble 
intercellular adhesion molecule-1], sVCAM-1 [soluble vas-
cular adhesion molecule-1], sE-selectin [soluble E-selectin], 
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Abstract—Microvascular dysfunction may be associated with worse cognitive performance. Most previous studies did not 
adjust for important confounders, evaluated only individual measures of microvascular dysfunction, and showed inconsistent 
results. We evaluated the association between a comprehensive set of measures of microvascular dysfunction and cognitive 
performance in the population-based Maastricht Study.We used cross-sectional data including 3011 participants (age 
59.5±8.2; 48.9% women; 26.5% type 2 diabetes mellitus [oversampled by design]). Measures of microvascular dysfunction 
included magnetic resonance imaging features of cerebral small vessel disease, plasma biomarkers of microvascular 
dysfunction, albuminuria, flicker light-induced retinal arteriolar and venular dilation response and heat-induced skin 
hyperemia. These measures were summarized into a microvascular dysfunction composite score. Cognitive domains 
assessed were memory, processing speed, and executive function. A cognitive function score was calculated as the sum 
of the scores on these 3 cognitive domains. The microvascular dysfunction score was associated with a worse cognitive 
function score (standardized β, −0.087 [95% CI, −0.127 to −0.047]), independent of age, education level, sex, type 2 
diabetes mellitus, smoking, alcohol use, hypertension, total/HDL (high-density lipoprotein) cholesterol ratio, triglycerides, 
lipid-modifying medication, prior cardiovascular disease, depression and plasma biomarkers of low-grade inflammation. 
The fully adjusted β-coefficient of the association between the microvascular dysfunction score and the cognitive function 
score was equivalent to 2 (range, 1–3) years of aging for each SD higher microvascular dysfunction score. The microvascular 
dysfunction score was associated with worse memory and processing speed but not with worse executive function. The 
present study shows that microvascular dysfunction is associated with worse cognitive performance.  (Hypertension. 
2020;75:237-245. DOI: 10.1161/HYPERTENSIONAHA.119.13023.) • Online Data Supplement
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and vWF [von Willebrand factor])4; and albuminuria (urinary 
albumin excretion [UAE]).5 In addition, direct measures include 
flicker light-induced retinal arteriolar and venular dilation re-
sponse6 and heat-induced skin hyperemia.6 CSVD features are 
closely linked to brain microvasculature structure, and evidence 
indicates that these features originate from cerebral MVD3,7,8; 
retinal arteriolar and venular dilation response are also closely 
linked to the brain microvasculature9; in addition, to the extent 
that MVD is a generalized phenomenon, plasma biomarkers of 
MVD, UAE, and skin hyperemia may also reflect brain MVD.10
These various measures of MVD (ie, features of CSVD, 
plasma biomarkers of MVD, UAE, retinal arteriolar and venular 
dilation response, and skin hyperemia) may, therefore, be sum-
marized into a total MVD composite score. A composite score 
reduces the influence of the biological variability of its com-
ponents, as we assume substantial overlap among mechanisms 
underlying the associations between the MVD measures and 
cognitive performance. Furthermore, it reduces the chance of a 
type 1 error. However, no study evaluated the association be-
tween such a MVD composite score and cognitive performance.
Some individual MVD measures, that is, CSVD features, 
plasma biomarkers of MVD and UAE, have been associated 
with worse cognitive performance,11–19 although not all meas-
ures consistently so.15,20,21 In the Maastricht Study, we pre-
viously found a cross-sectional association between higher 
UAE and worse cognitive performance.22 Previous studies, 
but not all, were relatively small (n<200),11,20 used selected 
populations,11,20,21 and may have been affected by residual 
confounding due to incomplete adjustment for education level 
and cardiovascular risk factors.11,12,14 Furthermore, most stud-
ies did not adjust for depression or low-grade inflammation, 
although both factors are linked to MVD and worse cognitive 
performance.14,23,24 Moreover, the associations between retinal 
arteriolar and venular dilation response and skin hyperemia, 
and cognitive performance have not been investigated.
We, therefore, investigated in a large population-based co-
hort with participants aged 40 to 75 years, whether a com-
posite score of MVD measures, including CSVD features, 
plasma biomarkers of MVD, UAE, retinal arteriolar and 
venular dilation response and skin hyperemia, is associated 
with worse cognitive performance. We additionally evaluated 
whether any such association was independent of age, edu-
cation level, sex, lifestyle factors, cardiovascular risk factors, 
current depression, and low-grade inflammation.
Methods
Study Population
We used data from The Maastricht Study, an observational popula-
tion-based cohort study. The rationale and methodology have been 
described previously.25 In brief, the study focuses on the etiology, 
pathophysiology, complications, and comorbidities of diabetes mel-
litus type 2 (T2D) and is characterized by an extensive phenotyp-
ing approach. Eligible for participation were all individuals aged 
40 to 75 years and living in the southern part of the Netherlands. 
Participants were recruited through mass media campaigns, the 
municipal registries, and the regional Diabetes Patient Registry 
via mailings. Recruitment was stratified according to known T2D 
status, with an oversampling of individuals with T2D, for reasons 
of efficiency. The present study includes cross-sectional data from 
3451 participants who completed the baseline survey between 
November 2010 and September 2013. The examinations of each 
participant were performed within a time window of three months. 
The study has been approved by the institutional medical ethical 
committee (NL31329.068.10) and the Ministry of Health, Welfare, 
and Sports of the Netherlands (Permit 131088-105234-PG). All par-
ticipants gave written informed consent. Data are available from 
The Maastricht Study for any researcher who meets the criteria for 
access to confidential data, and the corresponding author may be 
contacted to request data.
Microvascular Dysfunction
For all MVD measures, participants were asked to refrain from smok-
ing and drinking caffeine-containing beverages 3 hours before the 
measurement. A light meal was allowed until ≥90 minutes before 
the examination. For retinal measurements, pupils were dilated with 
0.5% tropicamide and 2.5% phenylephrine at least 15 minutes before 
the start of the examination. Skin blood flow measurements were per-
formed in a climate-controlled room at 24°C.
Cerebral Small Vessel Disease
Brain MRI measurements were implemented from December 2013 
onwards and were available in 2313 of 3451 participants (67%). 
Brain MRI was performed on a 3T MRI scanner (Siemens Magnetom 
Prisma-fit Syngo MR D13D Erlangen, Germany). We evaluated 4 
CSVD features, that is, total brain parenchyma volume, white matter 
hyperintensity volume, and presence of lacunar infarcts and cerebral 
microbleeds.3 A detailed description of the MRI protocol and the defi-
nitions of the CSVD features is provided in Item S1 in the online-only 
Data Supplement). The MRI protocol consisted of a 3D T
1
-weighted 
sequence, a fluid-attenuated inversion recovery sequence, a combined 
proton density and T
2
-weighted turbo spin-echo sequence and a sus-
ceptibility-weighted imaging sequence.26 Volumes were determined 
semi-automatically, and lacunar infarcts and cerebral microbleeds 
were scored manually.
Plasma Biomarkers of MVD
We measured 4 plasma biomarkers of MVD: sICAM-1, sVCAM-
1, sE-selectin, and vWF.4 sICAM-1, sVCAM-1, and sE-selectin 
were measured in EDTA plasma samples with commercially avail-
able 4-plex sandwich immunoassay kits with different standards 
and antibodies (Meso Scale Discovery, Rockville, Maryland). For 
this technique in this study, the intra- and inter-assay coefficients 
of variation were 10.3 and 8.4% for sICAM-1, 5.0 and 4.7% for 
sVCAM-1, and 2.9 and 7.4% for sE-selectin, respectively. vWF 
was quantified in citrate plasma using ELISA (Dako, Glostrup, 
Denmark). The intra- and inter-assay coefficients of variation were 
3.0 and 4.3%, respectively.
Urinary Albumin Excretion
We assessed UAE in two 24-hour urine samples. Urinary albumin 
concentration was measured with a standard immunoturbidimet-
ric assay by an automatic analyzer (due to a change of supplier, 
by the Beckman Synchron LX20 and the Roche Cobas 6000) and 
multiplied by collection volume to obtain 24-hour UAE.22 A uri-
nary albumin concentration below the detection limit of the assay 
was set at 1.5 mg/L (2 mg/L for the Beckman Synchron LX20 
and 3 mg/L for the Roche Cobas 6000) before multiplying by col-
lection volume. Only urine collections with a collection time be-
tween 20 and 28 hours were considered valid. If needed, UAE was 
extrapolated to 24-hour excretion. For this study, UAE was prefer-
ably based on the average of 2 (available in 91.3% of participants) 
24-hour urine collections.
Flicker Light-Induced Retinal Arteriolar and Venular 
Dilation Response
We measured retinal arteriolar and venular dilation response to 
flicker light exposure by the Dynamic Vessel Analyzer (Imedos, Jena, 
Germany), as previously described.6,27 A baseline recording of 50 
seconds was followed by 40-second flicker light exposure followed 
by a 60-second recovery period. We calculated baseline diameters 
(in measurement units) as the average diameter during 20 to 50 sec-
onds recording. For both the arteriolar and venular dilation response, 
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percentage dilation over baseline was calculated using the average 
dilation achieved at time points 10 and 40 seconds during the flicker 
stimulation period.
Heat-Induced Skin Hyperemia
We measured heat-induced skin hyperemia by laser Doppler flow-
metry (Perimed, Järfälla, Sweden), as previously described.6 We re-
corded unheated skin blood flow at the wrist, expressed in arbitrary 
perfusion units, for 2 minutes to serve as a baseline. After 2 minutes, 
the temperature of the laser Doppler probe was rapidly and locally 
increased to 44°C and was kept constant until the end of the regis-
tration. Skin hyperemia was expressed as the percentage increase in 
average perfusion units during the 23 minutes heating phase over the 
2 minutes average baseline perfusion units.
Cognitive Performance
We assessed cognitive performance by a concise neuropsycholog-
ical test battery.25 For statistical efficiency, we constructed a cog-
nitive function score by summation of standardized test scores of 
3 cognitive domains: memory, information processing speed, and 
executive function. A detailed description of methods used to cal-
culate domain-specific cognitive scores is provided in Item S2. We 
evaluated memory with the Verbal Learning Test.28 Information 
processing speed was evaluated with the Stroop Color-Word Test 
Part I and II,29 Concept Shifting Test Part A and B,30 and Letter-
Digit Substitution Test.31 Executive function was evaluated with the 
Stroop Color-Word Test Part III and Concept Shifting Test Part C.
Covariates
We determined diabetes mellitus status according to the World 
Health Organization 2006 criteria as normal glucose metabolism, 
prediabetes mellitus, or T2D.25 Education level was classified into 3 
groups: low (none, primary or lower vocational education only), in-
termediate (intermediate general secondary, intermediate vocational 
or higher general secondary education), and high (higher vocational 
education or university level of education). Alcohol consumption 
(none, low, high), smoking status (never, former, current), prior car-
diovascular disease (CVD), medication use, body mass index, office 
and ambulatory blood pressure, plasma lipid levels were determined 
as described previously.5,6,25 Hypertension was defined as an office 
blood pressure ≥140/90 mmHg or use of antihypertensive medica-
tion. The Mini-International Neuropsychiatric Interview was used 
to assess the presence of a current DSM-IV defined minor or major 
depressive episode, as described previously.25 Plasma biomarkers 
of low-grade inflammation were determined as described previ-
ously.32 These included high-sensitive CRP (C-reactive protein), 
SAA (serum amyloid A), IL-6 (interleukin-6), IL-8 (interleukin-8), 
and TNF-α (tumor necrosis factor-α).
Statistical Analysis
We selected all participants who had data available on all potential 
confounders, at least one individual MVD measure, and cognitive 
function. We did not impute missing values. We inversed total brain 
parenchyma volume, retinal arteriolar and venular dilation response 
and skin hyperemia so higher values indicated MVD. White matter 
hyperintensity volume was log-transformed (base 2) to normalize its 
skewed distribution. We analyzed UAE as a categorically (<15 [ref-
erence], 15–<30, and ≥30 mg/24 h), because UAE and cognitive per-
formance were nonlinearly associated.
We calculated a MVD composite score (MVD score) of all indi-
vidual MVD measures. For the total MVD score, the individual 12 
MVD measures (ie, 4 CSVD features, 4 plasma biomarkers of MVD, 
UAE, retinal arteriolar, and venular dilation responses and skin hy-
peremia) were standardized into z-scores. These z-scores were aver-
aged, and this average was standardized into the MVD score. The 
MVD score was calculated only in participants with data available 
on at least 9 of the 12 individual MVD measures. The Cronbach’s al-
pha for measuring internal consistency33 among the individual MVD 
measures was 0.52. This is considered acceptable internal consistency 
for different measures that may reflect, at least in part, the same un-
derlying construct.34
We used linear regression to investigate the association between 
the MVD score and the cognitive function score. All analyses were 
adjusted for age, education level, sex, T2D, body mass index, smok-
ing, alcohol use, hypertension, total/HDL cholesterol ratio, triglyc-
erides and lipid-modifying medication (model 1), and additionally 
for prior CVD, current depression and the plasma biomarkers of 
low-grade inflammation, that is, CRP, SAA, IL-6, IL-8, and TNF-α 
(model 2). Prior CVD, current depression and low-grade inflamma-
tion were entered into a separate model, because of the risk of over 
adjustment bias: these factors may be confounders but may also 
mediate the association between MVD and cognitive performance.
We tested interaction terms with age (dichotomized into <65 
and ≥65 years), education level, sex and T2D to evaluate whether 
the association between MVD and cognitive performance differed 
according to these factors. Interaction with age and education level 
was tested because MVD may be more strongly associated with 
worse cognitive performance in individuals with lower cognitive 
reserve, that is, in those with higher age and lower education level.35
Several sensitivity analyses were performed. First, we repeated the 
analysis using domain-specific cognitive function scores as the outcome, 
that is, memory, processing speed and executive function. Second, we re-
peated the analysis using each individual MVD measure as the determi-
nant. Third, we repeated the analysis with the MVD score in participants 
with data available on at least one, eight and 10 of the 12 individual MVD 
measures, respectively. Fourth, to test whether the association between 
the MVD score and cognitive function score was primarily determined 
by individual MVD measures, we repeated the analysis 5× after consec-
utively excluding from the MVD score the CSVD features, plasma bio-
markers of MVD, UAE, retinal arteriolar and venular dilation response 
and skin hyperemia, respectively. Fifth, we calculated composite scores 
for the CSVD features, plasma biomarkers of MVD and retinal arteriolar 
and venular dilation response, respectively, and evaluated the association 
between these composite scores and cognitive function score. The CSVD 
composite score was calculated as described previously.36 One point per 
CSVD feature was assigned for: fourth quartile lower total brain paren-
chyma volume and higher white matter hyperintensity volume; and pres-
ence of lacunar infarcts and cerebral microbleeds. The points for each 
feature were combined into the CSVD score (range, 0–4). For the plasma 
biomarkers of MVD score and retinal arteriolar and venular dilation re-
sponse scores, the z-scores of the 4 plasma biomarkers of MVD and the 
arteriolar and venular dilation responses were summed and standardized, 
respectively. Sixth, we repeated the analysis with additional adjustment 
for average 24-hour ambulatory systolic blood pressure,37 and class of an-
tihypertensive medication (ie, angiotensin-converting-enzyme inhibitors 
or angiotensin II receptor blockers versus other classes).38,39 Ambulatory 
systolic blood pressure is a better predictor of cognitive decline than of-
fice blood pressure.40 However, we did not adjust for ambulatory systolic 
blood pressure in the main analysis, because data on ambulatory systolic 
blood pressure were missing in a relatively large number of participants 
(n=424). Seventh, we repeated the analysis after stratification by T2D 
status, because by design individuals with T2D were oversampled in our 
cohort.
All analyses were performed with SPSS software (v22.0;IBM, 
Chicago). A P value of <0.05, and a P value for interaction of <0.10 
for interaction with sex and T2D were considered statistically sig-
nificant. For interaction with age and education level, a Bonferroni-
corrected P value of <0.05 was used instead of <0.10, because higher 
age and lower education level are considered reflections of the same 
construct, that is, lower cognitive reserve.
Results
Figure 1 shows the derivation of the final study population. 
In total, 3011 participants had data available on all poten-
tial confounders and at least one individual MVD measure. 
The MVD score was available in 2034 participants, CSVD 
features in 2002, plasma biomarkers of MVD in 2991, UAE 
in 2987, retinal arteriolar and venular dilation response in 
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1998, and skin hyperemia in 1457. These populations were 
comparable with regard to age, sex, and cardiovascular risk 
profile (Table S1). The table shows the characteristics of the 
study population and according to tertiles of the cognitive 
function score. Population-characteristics according to ter-
tiles of memory, processing speed, and executive function 
are provided in Tables S2 through S4. The study population 
had a mean age of 59.5 years, 48.9% were women, 26.5% 
had T2D (oversampled by design), and 41.1% had a high 
education level.
The MVD score was statistically significantly associated 
with a worse cognitive function score (Figure 2, models 1 and 
2). The regression coefficients of all covariates included in 
the fully adjusted model are provided in the Table S5. The 
fully adjusted β-coefficient of the association between one 
SD higher MVD score and the cognitive function score was 
equivalent to 2 (range, 1—3) years of aging.
Statistically, significant interaction was found between 
the MVD score and age (P value for interaction 0.045), indi-
cating that the association between MVD and worse cognitive 
function was stronger in participants aged ≥65 as compared 
with those aged <65 years. The association between the 
MVD score and cognitive function score stratified by age is 
provided in Table S6. We found no interactions with educa-
tion level, sex, and T2D.
Sensitivity Analyses
The MVD score was statistically significantly associated 
with worse memory and processing speed, but not with 
executive function (Figure 3). The individual MVD meas-
ures lower total brain parenchyma volume, higher white 
matter hyperintensity volume, sE-selectin, and UAE >30 
versus <15 mg/24 h were statistically significantly associ-
ated with a worse cognitive function score, but not lacunar 
infarcts, microbleeds, sICAM-1, sVCAM-1, vWF, UAE 15 
to <30 versus <15 mg/24 h, retinal arteriolar, and venular 
dilation responses or skin hyperemia (Figure 4 and Table 
S7). Results were similar when we repeated the analyses in 
participants with data available on at least one (n=3011), 8 
(n=2364), or 10 (n=1658) of the 12 individual MVD meas-
ures (Table S8), and when we consecutively excluded, from 
the MVD score, the CSVD features, plasma biomarkers 
of MVD, UAE, retinal arteriolar and venular dilation re-
sponse or skin hyperemia (Table S9). The composite scores 
of CSVD features and plasma biomarkers of MVD, but not 
of retinal arteriolar and venular dilation responses, were 
statistically significantly associated with a worse cognitive 
function score (Table S10). Results were similar when we 
additionally adjusted for ambulatory blood pressure (Table 
S11), or for class of antihypertensive medication (Table 
S12). Furthermore, no statistically significant interaction 
was found for T2D status in our main analysis (P value 
for interaction 0.94), and analysis stratified by T2D status 
showed that results were qualitatively similar in individuals 
with and without T2D (Table S13).
Discussion
The present cross-sectional study found that MVD is asso-
ciated with worse cognitive performance. This association 
was present for various MVD measures, including CSVD 
features, plasma biomarkers of MVD and UAE, but not ret-
inal arteriolar and venular dilation responses or skin hyper-
emia. Furthermore, this association was independent of age, 
education level, sex, lifestyle factors, cardiovascular risk fac-
tors, current depression, and low-grade inflammation. The 
strength of the association of each SD higher MVD score on 
the cognitive function score was equivalent to the effect of 
one to 3 years of aging.
Our study agrees with previous studies that showed an 
association between individual MVD measures, that is, 
CSVD features,15,41 plasma biomarkers of MVD11–14 and 
UAE,16 and worse cognitive performance. Some of these 
studies, but not all, found an association between MVD 
and worse cognitive performance or cognitive impairment. 
Our study expands this knowledge, as it is the first to com-
prehensively evaluate the association between MVD meas-
ures in various vascular beds and cognitive performance in 
a large population-based study with extensive adjustment 
for confounders.
The results were consistent across various MVD meas-
ures, except for retinal arteriolar and venular dilation 
responses and skin hyperemia, which were not statistically 
Figure 1. Derivation of the final study 
populations. *Missings were not mutually 
exclusive.
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Table. Characteristics of the Study Population
Baseline Characteristics
Total Study 
Population (n=3011)
Tertiles of Cognitive Function Score
Lowest (n=1003) Middle (n=1004) Highest (n=1004)
Age, y 59.5 (8.2) 64.0 (6.8) 59.9 (7.3) 54.7 (7.8)
Women, % 48.9 (1471) 36.5 (366) 45.4 (456) 64.6 (649)
Education level, %
  Low 15.7 (472) 31.6 (317) 11.8 (118) 3.7 (37)
  Intermediate 43.2 (1301) 44.8 (449) 45.1 (453) 39.7 (399)
  High 41.1 (1238) 23.6 (237) 43.1 (433) 56.6 (568)
Smoking status, %
  Never 34.9 (1051) 31.8 (319) 33.9 (340) 39.0 (392)
  Former 51.9 (1564) 52.8 (530) 53.8 (540) 49.2 (494)
  Current 13.2 (396) 15.4 (154) 12.4 (124) 11.8 (118)
Alcohol use, %
  None 18.0 (543) 21.7 (218) 16.0 (161) 16.3 (164)
  Low 55.5 (1671) 54.1 (543) 58.6 (588) 53.8 (540)
  High 26.5 (797) 24.1 (242) 25.4 (255) 29.9 (300)
Body mass index, kg/m2 27.1 (4.5) 28.0 (4.5) 27.0 (4.6) 26.2 (4.2)
Type 2 diabetes mellitus, % 26.5 (797) 41.2 (413) 25.0 (251) 13.2 (133)
Hypertension, % 55.4 (1667) 71.9 (721) 54.9 (551) 39.3 (395)
Total/HDL cholesterol ratio 3.7 (1.2) 3.7 (1.2) 3.8 (1.2) 3.6 (1.2)
Triglycerides, mmol/L 1.4 (0.9) 1.5 (0.9) 1.4 (0.8) 1.3 (0.8)
Lipid-modifying medication, % 34.9 (1050) 50.3 (505) 33.9 (340) 20.4 (205)
Prior cardiovascular disease, % 16.1 (486) 24.6 (247) 13.9 (140) 9.9 (99)
Current depression, % 3.7 (112) 5.4 (54) 3.6 (36) 2.2 (22)
Plasma biomarkers of low-grade inflammation composite score, SD* 0.0 (1.0) 0.2 (1.0) 0.0 (1.0) −0.3 (1.0)
Microvascular dysfunction measures†
Microvascular dysfunction composite score, SD 0.0 (1.0) 0.4 (1.1) 0.0 (0.9) −0.4 (0.8)
Cerebral small vessel disease features
Total brain parenchyma volume, mL 1138.4 (111.7) 1123.9 (111.8) 1150.3 (117.3) 1138.8 (104.6)
White matter hyperintensity volume, mL 0.2 (0.1–0.7) 0.4 (0.1–1.3) 0.2 (0.1–0.8) 0.1 (<0.1–0.4)
Presence of cerebral microbleeds 11.8 (237) 9.2 (92) 10.5 (73) 9.9 (72)
Presence of lacunar infarcts 5.4 (110) 6.7 (40) 6.4 (45) 3.4 (25)
Plasma biomarkers of microvascular dysfunction
Soluble ICAM-1, µg/L 352.7 (98.1) 372.3 (116.4) 348.1 (86.7) 337.8 (84.7)
Soluble VCAM-1, µg/L 425.1 (99.8) 445.2 (111.4) 422.9 (97.9) 407.1 (84.6)
Soluble E-selectin, µg/L 117.5 (64.2) 130.1 (76.4) 117.6 (56.3) 104.9 (55.4)
Von Willebrand Factor (%) 131.7 (47.8) 140.9 (51.1) 130.8 (45.9) 123.5 (44.7)
Urinary albumin excretion
Urinary albumin excretion ≥30 mg/24 h 8.1 (242) 13.4 (133) 7.0 (70) 3.9 (39)
Urinary albumin excretion 15–<30 mg/24 h 10.3 (308) 13.1 (130) 9.3 (93) 8.5 (85)
Flicker light-induced arteriolar and venular dilation response
Flicker light-induced arteriolar dilation response (%) 3.1 (2.8) 2.7 (2.9) 3.1 (2.7) 3.3 (2.7)
Flicker light-induced venular dilation response (%) 3.9 (2.2) 3.7 (2.2) 3.9 (2.1) 4.0 (2.2)
Heat-induced skin hyperemia (%) 1133.2 (781.5) 1006.2 (760.5) 1208.6 (859.6) 1192.0 (701.6)
Data are presented as percentage of participants (n), mean±SD (SD) or median (interquartile range). HDL indicates high-density lipoprotein; ICAM-1, 
intercellular adhesion molecule-1; and VCAM-1, vascular adhesion molecule-1.
*Expressed per SD.
†Data available for microvascular dysfunction composite score n=2034; total brain parenchyma volume and white matter hyperintensity volume n=2049; 
lacunar infarcts n=2046;cerebral microbleeds n=2012; sICAM-1; sVCAM-1; and sE-selectin n=3011; vWF n=2991; urinary albumin excretion n=2987; 
retinal arteriolar dilation response n=2018; retinal venular dilation response n=2049; and skin hyperemia n=1457.
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significantly associated with cognitive performance. Retinal 
arteriolar and venular dilation response and skin hyperemia 
may mostly reflect a more subtle form of endothelium-
dependent MVD, which may change acutely and may be 
reversible.27 For example, microvascular dilation responses 
in the retina or skin are transiently decreased directly after 
smoking42 and consumption of caffeine.43 In contrast, CSVD 
features, plasma biomarkers of MVD and UAE (all indirect 
measures of MVD) may reflect a more advanced stage of 
MVD.10 However, this study is the first to evaluate the associ-
ation between retinal arteriolar and venular dilation response 
and skin hyperemia and cognitive function, and this issue, 
therefore, requires further study.
In the present study, the association between MVD and 
worse cognitive performance was stronger in participants 
aged ≥65 years versus <65 years. This corresponds to our pre-
vious study on UAE and cognitive performance,22 and may be 
explained by a higher susceptibility for the detrimental effects 
of MVD on cognitive performance in the presence of a lower 
cognitive reserve with increasing age, in accordance with the 
cognitive reserve hypothesis.35
The observation that various MVD measures were associ-
ated with worse cognitive performance in our study supports 
the hypothesis that MVD may play a role in the pathophys-
iology of cognitive impairment. Earlier studies showed that 
impaired neurovascular coupling, cerebral autoregulation,2 
blood-brain barrier leakage,44 and impaired neurogenesis45 
are present in individuals with mild cognitive impairment and 
Alzheimer’s disease, and these disturbances may be the con-
sequence of MVD.2
Other underlying mechanisms may, however, explain the 
observed associations. First, MVD often coexists with CVD, 
and CVD is associated with worse cognitive performance.46 
However, our results were independent of a large set of cardi-
ovascular risk factors and prior CVD. Second, depression and 
low-grade inflammation are related to both MVD and worse 
cognitive performance. Our results remained, however, after 
adjustment for these factors. Third, other biological mecha-
nisms may underlie both MVD and worse cognitive perfor-
mance. For example, oxidative stress and lower brain-derived 
neurotrophic factor have been associated with both MVD and 
worse cognitive performance.47–50 However, data on oxidative 
stress and brain-derived neurotrophic factor were unavailable 
in our study; this requires further study.
Our study has several limitations. First, the cross-sec-
tional observational design precludes reaching causal conclu-
sions about the study findings. Second, the construction of 
the composite scores assumes that all its components reflect 
cerebral MVD, which is not necessarily true. Our a-priori de-
fined composite score was calculated with use of indirect and 
direct measures, which may reflect different forms of MVD 
(acute and reversible versus more advanced), and this may 
have led to an underestimation of the association between (a 
more advanced stage of) MVD and worse cognitive function. 
Third, no data were available on Alzheimer’s disease patholo-
gies, such as amyloid and tau deposition. It has been hypothe-
sized that these pathologies and MVD may act synergistically 
(ie, interact) in the development of cognitive impairment.51 
Such interaction might explain our observed association be-
tween MVD and worse memory, a domain most strongly 
associated with Alzheimer’s disease, and this issue requires 
further study. Fourth, lower total brain parenchyma volume 
is also determined by factors other than microvascular di-
sease, particularly the process of neurodegeneration. Fifth, 
Figure 2. Association between microvascular dysfunction score and 
cognitive function score. *Statistical significance (P<0.05). Data are 
available in n=2034. Results are expressed as SD (95% CI) worse cognitive 
function score per SD higher microvascular dysfunction score. Results 
were adjusted for age, education level, sex, diabetes mellitus type 2, body 
mass index, smoking status, alcohol use, hypertension, total/HDL (high-
density lipoprotein) cholesterol ratio, triglycerides, and lipid-modifying 
medication use (model 1), and additionally for prior cardiovascular disease, 
current depression and plasma biomarkers of low-grade inflammation 
(model 2).
Figure 3. Associations between microvascular 
dysfunction score and domain-specific 
cognitive function score. *Statistical 
significance (P<0.05). Data are available in 
n=2034. Results are expressed as SD (95% CI) 
worse domain-specific cognitive function score 
per SD higher microvascular dysfunction score. 
Adjustments as in Figure 2.
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the study population consisted of middle and early-old aged 
participants without dementia who were relatively well-edu-
cated and whose cardiovascular risk factors were relatively 
well-controlled. This may have led to an underestimation of 
the reported findings due to lower variation in cognitive per-
formance and relatively high cognitive reserve.
In conclusion, the present study shows that MVD is asso-
ciated with worse cognitive performance.
Perspectives
This study supports the hypothesis that MVD contributes to 
the development cognitive impairment. MVD might, there-
fore, be a target for prevention strategies of cognitive impair-
ment. Evidence suggests that lifestyle modifications, such as 
weight loss and exercise, may, at least in part, favorably in-
fluence MVD.52 In addition, drugs, such as renin-angiotensin-
aldosterone system inhibitors and antihyperglycemic agents 
(ie, metformin and GLP-1R (glucagon-like peptide 1 receptor) 
agonists), may improve microvascular function,52 possibly 
beyond their blood pressure- or glucose-lowering effects.52 
Future longitudinal studies are needed to further evaluate the 
association of MVD and cognitive decline and dementia.
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What Is New?
•	We tested for the first time the association between various microvas-
cular dysfunction measures and cognitive performance in a large popu-
lation-based study.
•	Microvascular dysfunction was measured by magnetic resonance im-
aging features of cerebral small vessel disease, plasma biomarkers of 
microvascular dysfunction, albuminuria, flicker light-induced retinal ar-
teriolar and venular dilation and skin hyperemia.
What Is Relevant?
•	We found an association between a composite score of microvascular 
dysfunction and worse cognitive performance.
•	Retinal arteriolar and venular dilation response and skin hyperemia were 
not associated with cognitive performance.
Summary
•	Our findings support the hypothesis that microvascular dysfunction con-
tributes to cognitive impairment.
•	Microvascular dysfunction may be a target for prevention strategies of 
cognitive impairment.
•	 Future longitudinal studies are needed to further evaluate the association 
of microvascular dysfunction and cognitive decline and dementia.
Novelty and Significance
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